Akoya Biosciences (AKYA) News Today

Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 3,090,000 shares, a decrease of 6.4% from the August 31st total of 3,300,000 shares. Currently, 14.0% of the company's stock are sold short. Based on an average daily volume of 182,500 shares, the short-interest ratio is presently 16.9 days.

Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) has been given an average rating of "Moderate Buy" by the nine brokerages that are covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the com

Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) saw a large increase in short interest in August. As of August 15th, there was short interest totalling 3,360,000 shares, an increase of 6.3% from the July 31st total of 3,160,000 shares. Currently, 15.2% of the company's stock are sold short. Based on an average trading volume of 272,000 shares, the short-interest ratio is presently 12.4 days.

Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine research firms that are currently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and five hav

Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totalling 3,160,000 shares, an increase of 6.4% from the July 15th total of 2,970,000 shares. Currently, 14.3% of the company's stock are short sold. Based on an average trading volume of 363,600 shares, the days-to-cover ratio is presently 8.7 days.

Piper Sandler decreased their price target on shares of Akoya Biosciences from $6.00 to $4.00 and set an "overweight" rating on the stock in a report on Tuesday.

Akoya Biosciences, Inc. (NASDAQ:AKYA - Free Report) - Investment analysts at Capital One Financial lifted their FY2024 earnings per share estimates for Akoya Biosciences in a research note issued on Tuesday, August 6th. Capital One Financial analyst T. Chiang now expects that the company will ear

Morgan Stanley downgraded shares of Akoya Biosciences from an "overweight" rating to an "equal weight" rating in a research note on Tuesday.

Akoya Biosciences (NASDAQ:AKYA - Get Free Report) issued its earnings results on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.27). Akoya Biosciences had a negative net margin of 72.68% and a negative return on equity of 111.80%. The business had revenue of $23.16 million during the quarter, compared to the consensus estimate of $23.61 million. During the same period last year, the business posted ($0.51) EPS.

Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation a

Silvercrest Asset Management Group LLC purchased a new position in shares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 580,834 shares of the com

Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) was the recipient of a large increase in short interest in June. As of June 30th, there was short interest totalling 2,600,000 shares, an increase of 15.6% from the June 15th total of 2,250,000 shares. Based on an average daily volume of 338,700 shares, the days-to-cover ratio is presently 7.7 days. Approximately 11.9% of the shares of the stock are sold short.

Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and eight have issued a buy recomme

Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 2,250,000 shares, a growth of 10.3% from the May 31st total of 2,040,000 shares. Based on an average daily trading volume, of 327,800 shares, the days-to-cover ratio is presently 6.9 days. Currently, 10.3% of the company's shares are sold short.

Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) CEO Brian Mckelligon sold 7,500 shares of the firm's stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $2.08, for a total value of $15,600.00. Following the sale, the chief executive officer now directly owns 224,733 shares in the company, valued at approximately $467,444.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) was the target of a significant growth in short interest during the month of May. As of May 15th, there was short interest totalling 1,160,000 shares, a growth of 11.5% from the April 30th total of 1,040,000 shares. Approximately 5.3% of the company's shares are short sold. Based on an average daily volume of 276,300 shares, the days-to-cover ratio is currently 4.2 days.

Akoya Biosciences, Inc. (NASDAQ:AKYA - Free Report) - Capital One Financial reduced their Q2 2024 earnings estimates for Akoya Biosciences in a research report issued to clients and investors on Monday, May 13th. Capital One Financial analyst T. Chiang now expects that the company will earn ($0.2

Canaccord Genuity Group reduced their price objective on Akoya Biosciences from $10.00 to $6.00 and set a "buy" rating for the company in a research report on Tuesday.

Peddock Capital Advisors LLC grew its position in Akoya Biosciences, Inc. (NASDAQ:AKYA - Free Report) by 546.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 290,720 shares of the company's stock after buying an additional 245,728

Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) saw a large decrease in short interest in March. As of March 31st, there was short interest totalling 988,400 shares, a decrease of 5.9% from the March 15th total of 1,050,000 shares. Based on an average daily trading volume, of 203,800 shares, the days-to-cover ratio is currently 4.8 days. Currently, 4.7% of the company's shares are sold short.